CAAS Capital Management’s ProKidney PROK Stock Holding History

CAAS Capital Management’s Portfolio PROK Stock Details PROK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-95,602	Closed	-$946K	–	1007
2022 Q1	$946K	Hold	95,602	–	–	0.04%	318
2021 Q4	$946K	Hold	95,602	–	–	0.02%	449
2021 Q3	$937K	Sell	95,602 -4,398	-4%	-$43.3K	0.02%	511
2021 Q2	$1.01M	Buy	+100,000	New	+$1.01M	0.02%	540

Other funds holding PROK

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

ACA

Arena Capital Advisors Los Angeles, California $208M AUM 11.42% 1-Year Est. Return

Sculptor Capital New York $9.61B AUM 27.49% 1-Year Est. Return

FTCM

First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Governors Lane New York $1.56B AUM 30.42% 1-Year Est. Return

CAAS Capital Management's PROK Position: Q2 2022 in Review

CAAS Capital Management sold out of ProKidney (PROK) in Q2 2022, closing a stake of 95,602 shares — an estimated $946K sold.

CAAS Capital Management first reported a position in PROK in Q2 2021 and held it in 4 quarters. The position peaked at $1.01M in Q2 2021. 67 funds tracked by Wall St. Rank hold PROK as of Q2 2022.

CAAS Capital Management reported no remaining ProKidney position as of Q2 2022 after selling out during the quarter.
CAAS Capital Management sold 95,602 ProKidney shares in Q2 2022, an estimated $946K.
CAAS Capital Management first reported a position in ProKidney in Q2 2021 and held it in 4 quarters.
CAAS Capital Management's ProKidney position peaked at $1.01M in Q2 2021.
67 funds tracked by Wall St. Rank held ProKidney as of Q2 2022.

Based on CAAS Capital Management's 13F filing for Q2 2022, filed 15 Aug 2022.